Phase Ib/II study of Resolaris (ATYR-1940) in interstitial lung disease (ILD) patients

Trial Profile

Phase Ib/II study of Resolaris (ATYR-1940) in interstitial lung disease (ILD) patients

Planning
Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2016

At a glance

  • Drugs ATYR 1940 (Primary)
  • Indications Interstitial lung diseases
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors aTyr Pharma
  • Most Recent Events

    • 11 Jan 2016 The company will make a determination as to whether to move forward with this trial for Resolaris (by the end of 2016), according to an aTyr Pharma media release.
    • 11 Jan 2016 Planned initiation date changed from 1 Jan 2016 to 1 Dec 2016, according to an aTyr Pharma media release.
    • 20 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top